{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:27:05Z","timestamp":1789720025180,"version":"4.0.1"},"reference-count":64,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T00:00:00Z","timestamp":1487030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T00:00:00Z","timestamp":1487030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacol Res Perspect"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1002\/prp2.297","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T11:34:58Z","timestamp":1487072098000},"page":"e00297","source":"Crossref","is-referenced-by-count":17,"title":["Adverse reactions to fluoroquinolones in the Nigerian population: an audit of reports submitted to the National Pharmacovigilance Centre from 2004 to 2016"],"prefix":"10.1002","volume":"5","author":[{"given":"Ibrahim A.","family":"Oreagba","sequence":"first","affiliation":[{"name":"Pharmacology, Therapeutics and Toxicology Department; College of Medicine; University of Lagos; Idiaraba Lagos Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3662-8476","authenticated-orcid":false,"given":"Kazeem A.","family":"Oshikoya","sequence":"additional","affiliation":[{"name":"Pharmacology Department; Lagos State University College of Medicine; Ikeja Lagos Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Comfort","family":"Ogar","sequence":"additional","affiliation":[{"name":"National Pharmacovigilance Centre; National Agency for Food and Drug Administration and Control; Abuja Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiodun O.","family":"Adefurin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine; Meharry Medical College; 1005 Dr. D.B. Todd Jr. Blvd. Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"National Pharmacovigilance Centre; National Agency for Food and Drug Administration and Control; Abuja Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olufunsho","family":"Awodele","sequence":"additional","affiliation":[{"name":"Pharmacology, Therapeutics and Toxicology Department; College of Medicine; University of Lagos; Idiaraba Lagos Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yetunde","family":"Oni","sequence":"additional","affiliation":[{"name":"National Pharmacovigilance Centre; National Agency for Food and Drug Administration and Control; Abuja Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,14]]},"reference":[{"key":"10.1002\/prp2.297-BIB0001|prp2297-cit-0001","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/adc.2010.208843","article-title":"Ciprofloxacin safety in paediatrics: a systematic review","volume":"96","author":"Adefurin","year":"2011","journal-title":"Arch Dis Child"},{"key":"10.1002\/prp2.297-BIB0002|prp2297-cit-0002","doi-asserted-by":"crossref","first-page":"328","DOI":"10.4236\/pp.2012.33044","article-title":"Fluoroquinolones reported hepatotoxicity","volume":"3","author":"Adikwu","year":"2012","journal-title":"Pharmacol Pharm"},{"key":"10.1002\/prp2.297-BIB0003|prp2297-cit-0003","doi-asserted-by":"crossref","first-page":"821","DOI":"10.15537\/smj.2015.7.11751","article-title":"Completeness of adverse drug reactions reports of the Saudi adverse event reporting system","volume":"36","author":"Alshammari","year":"2015","journal-title":"Saudi Med J"},{"key":"10.1002\/prp2.297-BIB0004|prp2297-cit-0004","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40264-015-0387-4","article-title":"Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase\u00ae","volume":"39","author":"Ampadu","year":"2016","journal-title":"Drug Saf"},{"key":"10.1002\/prp2.297-BIB0005|prp2297-cit-0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/0253-7613.125192","article-title":"A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions","volume":"46","author":"Belhekar","year":"2014","journal-title":"Indian J Pharmacol"},{"key":"10.1002\/prp2.297-BIB0006|prp2297-cit-0006","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/ajhp\/57.19.1791","article-title":"Levofloxacin use at an academic teaching institution","volume":"57","author":"Belliveau","year":"2000","journal-title":"Am J Health Syst Pharm"},{"key":"10.1002\/prp2.297-BIB0007|prp2297-cit-0007","doi-asserted-by":"crossref","first-page":"E475","DOI":"10.1503\/cmaj.121730","article-title":"Risk of acute kidney injury associated with the use of fluoroquinolones","volume":"185","author":"Bird","year":"2013","journal-title":"CMAJ"},{"key":"10.1002\/prp2.297-BIB0008|prp2297-cit-0008","doi-asserted-by":"publisher","first-page":"259476","DOI":"10.1155\/2014\/259476","article-title":"Effect of educational intervention on adverse drug reporting by physicians: a cross-sectional study","volume":"2014","author":"Bisht","year":"2014","journal-title":"ISRN Pharmacol"},{"key":"10.1002\/prp2.297-BIB0009|prp2297-cit-0009","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.4103\/0976-500X.120941","article-title":"Pharmacovigilance in Asia","volume":"4","author":"Biswas","year":"2013","journal-title":"J Pharmacol Pharmacother"},{"key":"10.1002\/prp2.297-BIB0010|prp2297-cit-0010","doi-asserted-by":"crossref","first-page":"e1034","DOI":"10.1542\/peds.2011-1496","article-title":"The use of systemic and topical fluoroquinolones","volume":"128","author":"Bradley","year":"2011","journal-title":"Pediatrics"},{"key":"10.1002\/prp2.297-BIB0011|prp2297-cit-0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/20469047.2015.1122384","article-title":"Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012","volume":"29","author":"Cliff-Eribo","year":"2016","journal-title":"Paediatr Int Child Health"},{"key":"10.1002\/prp2.297-BIB0012|prp2297-cit-0012","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2165\/00003495-199300453-00010","article-title":"Postmarketing surveillance of quinolones, 1990 to 1992","volume":"45","author":"Davey","year":"1993","journal-title":"Drugs"},{"key":"10.1002\/prp2.297-BIB0013|prp2297-cit-0013","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/BF01967015","article-title":"Post-marketing surveillance of quinolones 1988-1990","volume":"10","author":"Davey","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1002\/prp2.297-BIB0014|prp2297-cit-0014","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2174\/0929867013373435","article-title":"Adverse reactions to fluoroquinolones: an overview on mechanistic aspects","volume":"8","author":"Sarro","year":"2001","journal-title":"Curr Med Chem"},{"key":"10.1002\/prp2.297-BIB0015|prp2297-cit-0015","unstructured":"Drugwatch 2016 https:\/\/www.drugwatch.com\/cipro-levaquin-avelox\/"},{"key":"10.1002\/prp2.297-BIB0016|prp2297-cit-0016","first-page":"185","article-title":"DUE of ciprofloxacin in the treatment of urinary tract infections in hospitalized patients","volume":"27","author":"Dydek","year":"1992","journal-title":"Hosp Formul"},{"key":"10.1002\/prp2.297-BIB0017|prp2297-cit-0017","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1876818001102010047","article-title":"Impact of educational intervention for improving pharmacist knowledge in adverse drug reactions (ADR) Reporting: experience from Malaysia","volume":"2","author":"Elkalmi","year":"2011","journal-title":"Open Drug Saf J"},{"key":"10.1002\/prp2.297-BIB0018|prp2297-cit-0018","unstructured":"EMEA 2008a EMEA restricts use of oral norfloxacin drugs in UTIs www.who.int\/medicines\/publications\/newsletter\/2008news3.pdf"},{"key":"10.1002\/prp2.297-BIB0019|prp2297-cit-0019","doi-asserted-by":"crossref","unstructured":"EMEA 2008b EMEA recommends restricting the use of oral moxifloxacin-containing medicines www.who.int\/medicines\/publications\/newsletter\/2008news3.pdf","DOI":"10.2165\/00128415-200711710-00004"},{"key":"10.1002\/prp2.297-BIB0020|prp2297-cit-0020","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4314\/tjpr.v10i3.4","article-title":"Knowledge, attitude and practice of adverse drug reaction reporting among healthcare workers in a tertiary centre in Northern Nigeria","volume":"10","author":"Fadare","year":"2011","journal-title":"Trop J Pharm Res"},{"key":"10.1002\/prp2.297-BIB0021|prp2297-cit-0021","unstructured":"Federal Ministry of Health Nigeria, WHO, EC and DFID 2008 Standard treatment guidelines. Nigeria http:\/\/apps.who.int\/medicinedocs\/documents\/s17035e\/s17035e.pdf"},{"key":"10.1002\/prp2.297-BIB0022|prp2297-cit-0022","unstructured":"Federal Ministry of Health Nigeria 2016 http:\/\/www.who.int\/hiv\/pub\/guidelines\/nigeria_tb.pdf"},{"key":"10.1002\/prp2.297-BIB0023|prp2297-cit-0023","first-page":"403","article-title":"Dipyrone: the ban, the justification","volume":"34","author":"Fehintola","year":"2005","journal-title":"Afr J Med Med Sci"},{"key":"10.1002\/prp2.297-BIB0024|prp2297-cit-0024","doi-asserted-by":"crossref","first-page":"253S","DOI":"10.1592\/phco.21.16.253S.33993","article-title":"Fluoroquinolone adverse effects and drug interactions","volume":"21","author":"Fish","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1002\/prp2.297-BIB0025|prp2297-cit-0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF01642807","article-title":"Ciprofloxacin-induced hematuria","volume":"13","author":"Garlando","year":"1985","journal-title":"Infection"},{"key":"10.1002\/prp2.297-BIB0026|prp2297-cit-0026","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1086\/344768","article-title":"Widespread use of fluoroquinolones versus emerging resistance in pneumococci","volume":"35","author":"Goldstein","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1002\/prp2.297-BIB0027|prp2297-cit-0027","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1093\/clinids\/10.Supplement_1.S258","article-title":"Adverse effects of the fluoroquinolones","volume":"10","author":"Halkin","year":"1988","journal-title":"Rev Infect Dis"},{"key":"10.1002\/prp2.297-BIB0028|prp2297-cit-0028","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2165\/11537500-000000000-00000","article-title":"Completeness of published case reports on suspected adverse drug reactions: evaluation of 100 reports from a company safety database","volume":"33","author":"Impicciatore","year":"2010","journal-title":"Drug Saf"},{"key":"10.1002\/prp2.297-BIB0029|prp2297-cit-0029","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3233\/JRS-2008-0441","article-title":"Adverse drug reactions to fluoroquinolone antibiotics - Analysis of reports received in a tertiary care hospital","volume":"20","author":"Jose","year":"2008","journal-title":"Int J Risk Saf Med"},{"key":"10.1002\/prp2.297-BIB0030|prp2297-cit-0030","unstructured":"Kuriakose S 2016 http:\/\/sites.utexas.edu\/pharmacotherapy-rounds\/files\/2015\/09\/kuriakose11-21-14.pdf"},{"key":"10.1002\/prp2.297-BIB0031|prp2297-cit-0031","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s10096-004-1246-x","article-title":"Optimizing fluoroquinolone utilization in a public hospital: a prospective study of educational intervention","volume":"24","author":"Lacombe","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1002\/prp2.297-BIB0032|prp2297-cit-0032","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archinte.163.5.601","article-title":"Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use","volume":"163","author":"Lautenbach","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1002\/prp2.297-BIB0033|prp2297-cit-0033","first-page":"7","article-title":"Adverse drug reaction reports in Malaysia: comparison of causality assessments","volume":"5","author":"Lei","year":"2007","journal-title":"Malays J Pharm Sci"},{"key":"10.1002\/prp2.297-BIB0034|prp2297-cit-0034","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-200326020-00004","article-title":"Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions","volume":"26","author":"Leone","year":"2003","journal-title":"Drug Saf"},{"key":"10.1002\/prp2.297-BIB0035|prp2297-cit-0035","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40264-014-0256-6","article-title":"Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial","volume":"38","author":"Lopez-Gonzalez","year":"2015","journal-title":"Drug Saf"},{"key":"10.1002\/prp2.297-BIB0036|prp2297-cit-0036","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s10096-006-0221-0","article-title":"Prospective assessment of fluoroquinolone use in a teaching hospital","volume":"25","author":"Mean","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1002\/prp2.297-BIB0037|prp2297-cit-0037","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1345\/aph.1K347","article-title":"Safety concerns with fluoroquinolones","volume":"41","author":"Mehlhorn","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1002\/prp2.297-BIB0038|prp2297-cit-0038","unstructured":"NAFDAC 2016 National Agency for Food and Drug Administration and Control NAFDAC Act http:\/\/www.nafdac.gov.ng\/index.php\/about-nafdac\/nafdac-act"},{"key":"10.1002\/prp2.297-BIB0039|prp2297-cit-0039","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/BF01967014","article-title":"Side-effects of quinolones: comparisons between quinolones and other antibiotics","volume":"000","author":"Norrby","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1002\/prp2.297-BIB0040|prp2297-cit-0040","first-page":"70","article-title":"Fluoroquinolone use in children: the benefits and risks","volume":"33","author":"Oshikoya","year":"2006","journal-title":"Niger J Paediatr"},{"key":"10.1002\/prp2.297-BIB0041|prp2297-cit-0041","first-page":"1","article-title":"Treating children for malaria fever in the face of counterfeit and fake medicines","volume":"2","author":"Oshikoya","year":"2010","journal-title":"Int J Med Med Sci"},{"key":"10.1002\/prp2.297-BIB0042|prp2297-cit-0042","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1472-6904-9-14","article-title":"Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos Nigeria","volume":"9","author":"Oshikoya","year":"2009","journal-title":"BMC Clin Pharmacol"},{"key":"10.1002\/prp2.297-BIB0043|prp2297-cit-0043","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1086\/428055","article-title":"Antimicrobial safety: focus on fluoroquinolones","volume":"41","author":"Owens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1002\/prp2.297-BIB0044|prp2297-cit-0044","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/00365540701466223","article-title":"Fluoroquinolone prescriptions in a teaching hospital: a prospective audit","volume":"39","author":"Pulcini","year":"2007","journal-title":"Scand J Inf Dis"},{"key":"10.1002\/prp2.297-BIB0045|prp2297-cit-0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2125.1988.tb03356.x","article-title":"Spontaneous reporting of adverse drug reactions. I: the data","volume":"26","author":"Rawlins","year":"1988","journal-title":"Br J Clin Pharmacol"},{"key":"10.1002\/prp2.297-BIB0046|prp2297-cit-0046","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3233\/JRS-2007-420","article-title":"Causality assessment of spontaneously reported adverse drug events: comparison of WHO-UMC criteria and Naranjo probability scale","volume":"19","author":"Rehan","year":"2007","journal-title":"Int J Risk Saf Med"},{"key":"10.1002\/prp2.297-BIB0047|prp2297-cit-0047","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4103\/0255-0857.158564","article-title":"Adverse drug reactions profile of antimicrobials: a 3-year experience, from a tertiary care teaching hospital of India","volume":"33","author":"Richa","year":"2015","journal-title":"Indian J Med Microbiol"},{"key":"10.1002\/prp2.297-BIB0048|prp2297-cit-0048","first-page":"1781","article-title":"Adverse drug reactions: types and treatment options","volume":"68","author":"Riedl","year":"2003","journal-title":"Am Fam Physician"},{"key":"10.1002\/prp2.297-BIB0049|prp2297-cit-0049","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/BF03261979","article-title":"Evaluation of completeness of suspected adverse drug reaction reports submitted to the Mexican national pharmacovigilance centre: a cross-sectional period-prevalence study","volume":"35","author":"S\u00e1nchez-S\u00e1nchez","year":"2012","journal-title":"Drug Saf"},{"key":"10.1002\/prp2.297-BIB0050|prp2297-cit-0050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jsps.2013.06.004","article-title":"A prospective study on adverse drug reactions of antibiotics in a tertiary care hospital","volume":"22","author":"Shamna","year":"2014","journal-title":"Saudi Pharm J"},{"key":"10.1002\/prp2.297-BIB0051|prp2297-cit-0051","first-page":"606","article-title":"Adverse drug reaction-causality assessment","volume":"1","author":"Srinivasan","year":"2011","journal-title":"Int J Res Pharm Chem"},{"key":"10.1002\/prp2.297-BIB0052|prp2297-cit-0052","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/14740338.2013.796362","article-title":"Risks associated with the therapeutic use of fluoroquinolones","volume":"12","author":"Stahlmann","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"10.1002\/prp2.297-BIB0053|prp2297-cit-0053","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2471\/BLT.12.105445","article-title":"Antibiotics Smart Use: a workable model for promoting the rational use of medicines in Thailand","volume":"90","author":"Sumpradit","year":"2012","journal-title":"Bull World Health Organ"},{"key":"10.1002\/prp2.297-BIB0054|prp2297-cit-0054","unstructured":"The Uppsala Monitoring Centre 2016a http:\/\/www.who-umc.org\/DynPage.aspx?id=96979&mn1=7347&mn2=7469"},{"key":"10.1002\/prp2.297-BIB0055|prp2297-cit-0055","unstructured":"The Uppsala Monitoring Centre 2016b http:\/\/who-umc.org\/Graphics\/24734.pdf"},{"key":"10.1002\/prp2.297-BIB0056|prp2297-cit-0056","unstructured":"The Uppsala Monitoring Centre 2016c http:\/\/www.umc-products.com\/graphics\/28010.pdf"},{"key":"10.1002\/prp2.297-BIB0057|prp2297-cit-0057","first-page":"8","article-title":"Comparative quality of fluoroquinolone tablets marketed in some towns in Northern Nigeria","volume":"4","author":"Tytler","year":"2007","journal-title":"J Pharm Bioresources"},{"key":"10.1002\/prp2.297-BIB0058|prp2297-cit-0058","unstructured":"USFDA 2016 http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm500143.htm"},{"key":"10.1002\/prp2.297-BIB0059|prp2297-cit-0059","first-page":"141","article-title":"Drug resistant mycobacterium tuberculosis in tertiary hospital South East Nigeria","volume":"3","author":"Uzoewulu","year":"2014","journal-title":"J Med Microb Diagn"},{"key":"10.1002\/prp2.297-BIB0060|prp2297-cit-0060","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2125.2005.02504.x","article-title":"Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital","volume":"60","author":"Vallano","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1002\/prp2.297-BIB0061|prp2297-cit-0061","unstructured":"WHO 2002 http:\/\/apps.who.int\/medicinedocs\/en\/d\/Jh3011e\/"},{"key":"10.1002\/prp2.297-BIB0062|prp2297-cit-0062","unstructured":"WHO 2014 http:\/\/www.who.int\/tb\/publications\/global_report\/gtbr14_main_text.pdf"},{"key":"10.1002\/prp2.297-BIB0063|prp2297-cit-0063","unstructured":"WHO 2016a http:\/\/www.who-umc.org\/DynPage.aspx?id=100653&mn1=7347&mn2=7252&mn3=7322&mn4=7442"},{"key":"10.1002\/prp2.297-BIB0064|prp2297-cit-0064","unstructured":"WHO 2016b http:\/\/www.who.int\/tb\/MDRTBguidelines2016.pdf"}],"container-title":["Pharmacology Research & Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fprp2.297","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/prp2.297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T10:13:45Z","timestamp":1749982425000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/prp2.297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,14]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"URL":"https:\/\/doi.org\/10.1002\/prp2.297","archive":["Portico"],"relation":{},"ISSN":["2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2,14]]}}}